HESTERBIO2,270.00

Hester Biosciences Limited

· Pharma & Health
₹ CrorePeersWINDLASSYNCOMFNGLFINEINDOCOSAIPARENTJAGSNPHARMPANACEABIOMcap ₹1,931 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation17.216.818.9
+ Finance Costs19.512.210.3
+ Interest Income-1.9-2.0-1.6
+ Fair Value (Gains) / Losses0.00.0-1.8
+ Unrealised FX (Gain) / Loss-0.1-0.810.9
+ Other Non-cash Items-5.84.46.2
+ Other — Cash Effects are Investing / Financing0.00.0-2.9
Changes in Working Capital
+ Inventories9.25.2-3.6
+ Trade Receivables — Current0.41.6-29.1
+ Other Financial Assets — Current0.80.5-0.2
+ Other Financial Assets — Non-current0.1-0.92.2
+ Other Current Assets2.52.0-0.7
+ Other Non-current Assets0.00.0-0.2
+ Trade Payables — Current-3.53.7-3.1
+ Other Financial Liabilities — Current1.2-1.42.3
+ Other Financial Liabilities — Non-current0.00.00.2
+ Other Current Liabilities-7.9-0.10.2
+ Other Non-current Liabilities0.0-0.40.0
+ Provisions — Current0.3-0.3-0.4
+ Provisions — Non-current0.60.21.1
Cash from Operating Activities
Profit Before Tax (per I/S)27.335.569.5150.0
+ Total Adjustments (incl. Working Capital)32.540.58.8
Cash from Operations (pre-tax)59.876.078.3
+ Income Taxes Paid11.711.514.1
Cash from Operating Activities48.164.564.1
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)24.420.617.8
+ Disp of Fixed Assets0.10.30.4
+ Disp of Subsidiaries / Businesses (net)0.00.07.5
+ Loans & Advances Repaid0.00.05.5
+ Interest Received — Investing1.90.82.0
+ Other Inflows / (Outflows) — Investing-0.20.5-0.9
Cash from Investing Activities-22.7-19.0-3.3
Cash from Financing Activities
+ Proceeds from Borrowings20.50.00.0
+ Repayment of Borrowings50.533.135.9
+ Payment of Lease Liabilities0.30.30.3
+ Interest Paid14.913.16.6
+ Dividends Paid6.85.26.0
+ Other Inflows / (Outflows) — Financing26.00.00.0
Cash from Financing Activities-26.0-51.7-48.8
Net Changes in Cash (pre-FX)-0.6-6.212.1
+ Effect of FX Rate Changes on Cash0.2-0.5-14.9
Net Changes in Cash-0.4-6.7-2.8
Closing Cash12.7
Reference Items
EBITDA53.761.186.786.6
EBITDA Margin %17.6219.6226.0526.59
Free Cash Flow (CFO − Capex)23.743.946.346.3
Free Cash Flow to Equity-0.520.2
Free Cash Flow per Basic Share27.9051.6354.4454.44
Price to Free Cash Flow41.70
Cash Flow to Net Income2.272.241.12
Cash Paid for Taxes11.711.514.1
Cash Paid for Interest14.913.16.6
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.